1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. BELLUS Health Inc.
  6. News
  7. Summary
    BLU   CA07987C2040

BELLUS HEALTH INC.

(BLU)
  Report
Delayed Toronto Stock Exchange  -  05/20 04:00:00 pm EDT
10.59 CAD   -2.58%
05/11BELLUS : Q1 Earnings Snapshot
AQ
05/11Bellus Health Reports Q1 Net Loss of US$14.4 Million, Provides Update
MT
05/11BELLUS Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

RBC Capital Keeps Outperform/Speculative Risk Rating, US$14 TP on Bellus Health

01/11/2022 | 01:08pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BELLUS HEALTH INC. -2.58% 10.59 Delayed Quote.4.13%
ON SEMICONDUCTOR CORPORATION -1.33% 55.76 Delayed Quote.-16.87%
All news about BELLUS HEALTH INC.
05/11BELLUS : Q1 Earnings Snapshot
AQ
05/11Bellus Health Reports Q1 Net Loss of US$14.4 Million, Provides Update
MT
05/11BELLUS Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/11Earnings Flash (BLU.TO) BELLUS HEALTH Says Ended Q1 2022 with US$234.0 million in cash,..
MT
05/11Earnings Flash (BLU.TO) BELLUS HEALTH Posts Q1 Basic and Diluted Loss US$0.13
MT
05/11BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
BU
05/11TRANSCRIPT : BELLUS Health Inc. - Shareholder/Analyst Call
CI
05/02BELLUS HEALTH : to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of B..
PU
05/02BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of ..
BU
05/02BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of ..
CI
More news
Analyst Recommendations on BELLUS HEALTH INC.
More recommendations
Financials
Sales 2022 0,34 M 0,26 M 0,26 M
Net income 2022 -103 M -80,3 M -80,3 M
Net Debt 2022 - - -
P/E ratio 2022 -11,6x
Yield 2022 -
Capitalization 1 130 M 885 M 885 M
Capi. / Sales 2022 3 353x
Capi. / Sales 2023 881x
Nbr of Employees 40
Free-Float 81,2%
Chart BELLUS HEALTH INC.
Duration : Period :
BELLUS Health Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BELLUS HEALTH INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 10,59 CAD
Average target price 18,50 CAD
Spread / Average Target 74,7%
EPS Revisions
Managers and Directors
Roberto Bellini President, Chief Executive Officer & Director
Ramzi Benamar Chief Financial Officer
Francesco Bellini Chairman
Denis Garceau Chief Scientific Officer
Catherine M. Bonuccelli Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BELLUS HEALTH INC.4.13%881
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612